Comparação Indireta Ajustada à Correspondência de Sotorasib Plus Panitumumab Versus Trifluridina/Tipiracil Plus Bevacizumab em Câncer Colorectal Metastático Chemorefractory
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Clinical colorectal cancer
- Publicado em
- 23 abr 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer
Lisa Salvatore, Marwan Fakih, Yasutoshi Kuboki, David S. Hong, Dominik Paul Modest, Julien Taieb, Timothy Jay Price, Chiara Cremolini, Istvan Matyas Majer, Marko Rehn et al.
Descritores MeSH
- Antineoplastic Combined Chemotherapy Protocols
- Colorectal Neoplasms
- Progression-Free Survival
- Adult
- Aged
- Drug Combinations
- Female
- Humans
- Indoles
- Male
Veja também
Estudos relacionados
- Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis
- Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
- Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT Trial
- Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis
- Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C